Discovery of tetrahydro-β-carbolines as inhibitors of the mitotic kinesin KSP
摘要:
Inhibitors of kinesin spindle protein (KSP) are a promising class of anticancer agents that cause mitotic arrest in cells from a failure to form functional bipolar mitotic spindles. Here, we report the synthesis and biological evaluation of a novel series of tetrahydro-beta-carboline analogs based on the structure of the known KSP inhibitor HR22C16. Preferred compounds 11b, 12a and 19b were identified as potent inhibitors in a KSP ATPase assay with good anti-proliferative activity in A549 cells. (C) 2010 Elsevier Ltd. All rights reserved.
Design, Synthesis, and Structure–Activity Relationship of a Novel Series of GluN2C-Selective Potentiators
作者:Sommer S. Zimmerman、Alpa Khatri、Ethel C. Garnier-Amblard、Praseeda Mullasseril、Natalie L. Kurtkaya、Stefka Gyoneva、Kasper B. Hansen、Stephen F. Traynelis、Dennis C. Liotta
DOI:10.1021/jm401695d
日期:2014.3.27
herein describe a novel series of pyrrolidinones that selectively potentiate only NMDA receptors that contain the GluN2C subunit. The most active analogues tested were over 100-fold selective for recombinant GluN2C-containing receptors over GluN2A/B/D-containing NMDA receptors as well as AMPA and kainate receptors. This series represents the first class of allosteric potentiators that are selective
[EN] FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERARY<br/>[FR] DIAMIDES IMIDODICARBONIMIDIQUES LIÉS À UN ALKYLÈNE BICYCLIQUE FUSIONNÉ, PROCÉDÉS DE SYNTHÈSE ET UTILISATIONS DANS UNE THÉRAPIE
申请人:NOVATARG INC
公开号:WO2018106907A1
公开(公告)日:2018-06-14
The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3- yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3- yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5' adenosine monophosphate-activated protein kinase (AMPK).
N-Fluorenyltryptamines as a Useful Platform for Catalytic Enantioselective Pictet–Spengler Reactions
作者:Alafate Adili、Aniket V. Sole、Daniel Seidel、Bishwaprava Das、Megan E. Matter
DOI:10.1055/a-1970-4452
日期:——
thiourea–carboxylic acid catalyst, N-9-fluorenyltryptamines undergo highly enantioselective Pictet–Spenglerreactions with a range of aldehydes. The reaction works particularly well with aromatic aldehydes, tolerating electronically diverse substituents in all ring positions. Electron-deficient tryptamines are viable substrates. Removal of the fluorenyl protecting group is readily accomplished without deterioration
在硫脲-羧酸催化剂存在下,N -9-芴基色胺与一系列醛发生高度对映选择性的 Pictet-Spengler 反应。该反应特别适用于芳香醛,在所有环位上都可以接受电子不同的取代基。缺电子色胺是可行的底物。去除芴基保护基团很容易完成,而不会使产物 ee 变差。
Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
申请人:NovaTarg, Inc.
公开号:US11261157B2
公开(公告)日:2022-03-01
The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5′ adenosine monophosphate-activated protein kinase (AMPK).
本发明提供了新颖的融合双环烯基连接的咪唑二碳酰亚胺二酰胺。特别是,本发明描述了 N-[2-(吲哚-3-基)亚烷基]连接的咪唑二碳酰亚胺二酰胺和 N-[2-(吡咯并吡啶-3-基)亚烷基]连接的咪唑二碳酰亚胺二酰胺(式 (I) 或式 (II) 的化合物)及其用途。本发明的化合物被认为是有机阳离子转运体选择性化合物,可用于治疗由 5′单磷酸腺苷激活蛋白激酶(AMPK)活性降低引起的疾病和病症。
FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY
申请人:NovaTarg, Inc.
公开号:US20190345103A1
公开(公告)日:2019-11-14
The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5′ adenosine monophosphate-activated protein kinase (AMPK).